In 2010, the company switched to a net profit of RON57.3 million, from a loss of RON2.8 million a year before.
Zentiva also estimates 4% lower net sales for this year, at RON245.8 million, according to the 2011 budget that will be discussed by shareholders on April 28.
Production costs are seen at RON109.9 million in 2011, while expenses for sales and marketing activities are estimated to total RON53.4 million. The general and administrative costs are seen at RON24.8 million, while the research and development program might cost RON4.3 million.
On April 28, the holders will also discuss the Board’s proposal to pay the first dividends since Zentiva started floating on the bourse, worth of RON125 million, and some RON50 million loans given to main holder, French pharmaceutical group Sanofi-Aventis.
Zentiva has a share capital of RON41.6 million, divided into 416.9 million shares with a face value of RON0.1.
Sanofi-Aventis owns a 74.9% stake in Zentiva Romania.
Friday in Bucharest, Zentiva Romania shares traded up 2.86% at RON1.54.